Effect of Yanghetang in Chemotherapeutic Enhancement Response Among Patients of Advanced Gastric Cancer with Syndrome of Yang Deficiency and Cancer Inflammatory Factors Treg and MDSCs

TIAN Tong-de; YANG Feng; YUE Li-yun; WANG Xin-xin; SHI Bian

doi:10.13422/j.cnki.syfjx.2016220160

您当前的位置：

首页 >

文章列表页 >

Effect of Yanghetang in Chemotherapeutic Enhancement Response Among Patients of Advanced Gastric Cancer with Syndrome of Yang Deficiency and Cancer Inflammatory Factors Treg and MDSCs

更新时间：2024-01-04

- Effect of Yanghetang in Chemotherapeutic Enhancement Response Among Patients of Advanced Gastric Cancer with Syndrome of Yang Deficiency and Cancer Inflammatory Factors Treg and MDSCs
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 22, Issue 22, Pages: 160-164(2016)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2016220160
  CLC： R285.6
- Published：2016
- 稿件说明：
移动端阅览
TIAN Tong-de, YANG Feng, YUE Li-yun, et al. Effect of Yanghetang in Chemotherapeutic Enhancement Response Among Patients of Advanced Gastric Cancer with Syndrome of Yang Deficiency and Cancer Inflammatory Factors Treg and MDSCs[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(22): 160-164.
DOI：

TIAN Tong-de, YANG Feng, YUE Li-yun, et al. Effect of Yanghetang in Chemotherapeutic Enhancement Response Among Patients of Advanced Gastric Cancer with Syndrome of Yang Deficiency and Cancer Inflammatory Factors Treg and MDSCs[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(22): 160-164. DOI： 10.13422/j.cnki.syfjx.2016220160.

摘要

目的：观察阳和汤对晚期胃癌“阳虚证”患者化疗的增效作用，并从肿瘤相关炎症微环境的角度，探讨其作用机制。方法： 120例表现为“阳虚证”的晚期胃癌患者随机分为两组，观察组（60例）予阳和汤加减联合多柔比星（DOX）方案化疗（3周为1疗程），对照组（60例）则单纯给予同方案化疗，3个疗程化疗结束后，评价两组患者的生活质量、近期疗效，并检测炎性免疫因子的血清水平和外周血髓源性抑制细胞（MDSCs），调节性T细胞（Treg）所占外周血单个核细胞（PMBC）的比率变化。结果：观察组患者的Karnofsky评分的改善率和有效率分别为31.7%，85.0%，显著高于对照组13.3%，55.0%（P<0.05）。观察组的有效率和疾病控制率分别为45.0%，85.0%，明显优于对照组26.7%，68.3%（P<0.05）。与治疗前比较，观察组治疗后外周血缺氧诱导因子-1α（HIF-1α）显著降低（P<0.01），白细胞介素-10（IL-10），转化生长因子-β1（TGF-β1），肿瘤坏死因子-α（TNF-α），单核细胞趋化蛋白-1（MCP-1）水平及MDSCs，Treg细胞所占比率均明显降低（P<0.05），干扰素-γ（IFN-γ）水平显著升高（P<0.01），对照组治疗后MDSCs细胞比率明显降低（P<0.05），IFN-γ明显升高（P<0.05）。两组患者治疗后比较，观察组HIF-1α，IL-10，TGF-β1，TNF-α，MCP-1水平及MDSCs，Treg细胞比率均明显降低（P<0.05），IFN-γ水平明显升高（P<0.05）。结论：阳和汤能够显著提高晚期胃癌阳虚证患者化疗的近期疗效和生活质量，通过改善肿瘤相关炎症微环境，重塑肿瘤免疫可能是其发挥化疗增效的重要机制。

Abstract

Objective: To observe the effect of Yanghetang in chemotherapeutic enhancement response among advanced gastric cancer with syndrome of Yang deficiency

and investigate its mechanism from the perspective of cancer-related inflammation micro-environment. Method: A total of 120 patients of advanced gastric cancer with syndrome of Yang deficiency were randomly divided into two groups

the treatment group (60 cases) that was treated with modified Yanghe Tang plus Doxorubicin (DOX) chemotherapy (3 weeks for a course)

and the control group (60 cases) that was treated with the same chemotherapy alone. After three courses of chemotherapy

quality of life

short-term effectiveness of the two groups were valuated

and serum levels of inflammatory immune factors

and changes in ratio of peripheral Myeloid-derived suppressor cells (MDSCs)

regulatory T cells (Treg) in peripheral blood mononuclear cell (PBMC) between both groups were detected. Result: Improvement rate and effective rate of Karnofsky score in patients of the treatment group were 31.7% and 85.0%

respectively

which were higher than 13.3% and 55.0% of control group (P<0.05). Short-term effectiveness and disease control rate of treatment group were 45.0% and 85.0%

respectively

which were significantly better than 26.7% and 68.3% of control group (P<0.05). Compared with pre-treatment

treatment group showed significant decrease in serum hypoxia induced factor-1α (HIF-1α) (P<0.01)

interlukin-10 (IL-10)

transforming growth factor-β1 (TGF-β1)

tumor necrosis factor-α (TNF-α)

monocyte chemotactic protein-1 (MCP-1) and MDSCs

and percentage of Treg (P<0.05)

and increases in serum IFN-γ (P<0.05)

whereas control group only showed significant advantage of higher levels of IFN-γ and lower percentage of peripheral MDSCs than pre-treatment (P<0.05). In comparison between two groups after treatment

treatment group showed significantly lower serum levels of HIF-1α

IL-10

TGF-β

TNF-α

MCP-1

ratio of peripheral MDSCs

and Treg (P<0.05)

and higher serum levels of IFN-γ than control group (P<0.05). Conclusion: Yanghetang can significantly improve the efficacy and quality of life of gastric cancer patients with syndrome of Yang deficiency treated with chemotherapy. Its effect in chemotherapeutic enhancement response may be correlated with its important mechanisms in remodeling cancer immunity by improving the cancer-related inflammatory micro-environment.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism of Action of Yanghetang in Regulating Macrophage Polarization to Alleviate Osteoarthritis Based on PI3K/Akt/NF-κB Signaling Pathway

Chinese and Western Medicine Treatment of Gastric Cancer via Ferroptosis： A Review

Screening of Anti-breast Cancer Active Ingredients in Famous Classical Formula Yanghetang

Mechanism of Weiliuan Mixture in Regulating Ferroptosis and Inhibiting Progression of Gastric Cancer Based on Transcriptome

Weichang'an Prescription-containing Serum Induces Ferroptosis of Gastric Cancer MKN-45 Cells

Related Author

GENG Xiaojuan

PENG Yun

ZHUANG Rujie

MA Yibin

LI Xiaojing

LIU Qiuhua

WANG Jie

GUO Yuxi

Related Institution

College of Pharmaceutical Sciences， Zhejiang Chinese Medical University

Zhejiang Chinese Medicine University Affiliated Four-provinces Marginal Hospital of Traditional Chinese Medicine

The First Affiliated Hospital of Zhejiang Chinese Medical University （Zhejiang Provincial Hospital of Chinese Medicine）

Graduate School， Hebei University of Chinese Medicine

Hebei Provincial Hospital of Traditional Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰